Forest Laboratories, Inc. FRX +0.94% and Gedeon Richter Plc today announced preliminary top-line results from a Phase III clinical trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder. Cariprazine is also being investigated in clinical studies for patients with schizophrenia, bipolar depression, and as an adjunct treatment in MDD.

Read the full story here.

Advertisements